IL220939D0 - Compounds and methods - Google Patents

Compounds and methods

Info

Publication number
IL220939D0
IL220939D0 IL220939A IL22093912A IL220939D0 IL 220939 D0 IL220939 D0 IL 220939D0 IL 220939 A IL220939 A IL 220939A IL 22093912 A IL22093912 A IL 22093912A IL 220939 D0 IL220939 D0 IL 220939D0
Authority
IL
Israel
Prior art keywords
compounds
methods
Prior art date
Application number
IL220939A
Other versions
IL220939A (en
Original Assignee
Tempero Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29457510P priority Critical
Priority to PCT/US2011/021089 priority patent/WO2011088181A1/en
Application filed by Tempero Pharmaceuticals Inc filed Critical Tempero Pharmaceuticals Inc
Publication of IL220939D0 publication Critical patent/IL220939D0/en
Publication of IL220939A publication Critical patent/IL220939A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y02A50/411
    • Y02A50/463
IL220939A 2010-01-13 2012-07-12 Compounds for the inhibition of hdac and pharmaceutical compositions comprising them IL220939A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29457510P true 2010-01-13 2010-01-13
PCT/US2011/021089 WO2011088181A1 (en) 2010-01-13 2011-01-13 Compounds and methods

Publications (2)

Publication Number Publication Date
IL220939D0 true IL220939D0 (en) 2012-09-24
IL220939A IL220939A (en) 2016-11-30

Family

ID=44304635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL220939A IL220939A (en) 2010-01-13 2012-07-12 Compounds for the inhibition of hdac and pharmaceutical compositions comprising them

Country Status (15)

Country Link
US (2) US8901156B2 (en)
EP (1) EP2533783B8 (en)
JP (1) JP6017313B2 (en)
KR (1) KR101781663B1 (en)
CN (1) CN103221047B (en)
AU (1) AU2011205283B2 (en)
BR (1) BR112012017441B1 (en)
CA (1) CA2787018A1 (en)
EA (1) EA022964B1 (en)
ES (1) ES2560627T3 (en)
IL (1) IL220939A (en)
MX (1) MX341133B (en)
SG (1) SG182401A1 (en)
WO (1) WO2011088181A1 (en)
ZA (1) ZA201205125B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517281A (en) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. Compounds and methods
CN103764635B (en) * 2011-07-08 2016-01-20 诺华股份有限公司 New trifluoromethyl-oxadiazole derivative and the purposes in disease treatment thereof
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
JP5966014B2 (en) * 2011-11-28 2016-08-10 ノバルティス アーゲー Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases
US9072301B2 (en) 2012-02-03 2015-07-07 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113778A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9055750B2 (en) 2012-02-03 2015-06-16 Basf Se Fungicidal pyrimidine compounds
WO2013113787A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
NZ704666A (en) * 2012-08-23 2018-05-25 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
CN102826985B (en) * 2012-09-18 2015-08-19 厦门大学 A kind of preparation method of 1-(3,4,5-trihydroxy-) phenyl-1-alkyl ketone
JP6423372B2 (en) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
CN103214327A (en) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 Aromatic ring or heteroaromatic trifluoromethyl ketone compound and preparation method thereof
CA2921294A1 (en) * 2013-08-21 2015-02-26 Alios Biopharma, Inc. Antiviral compounds
WO2015057659A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
JP6483666B2 (en) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 Selectively substituted quinoline compounds
PL226024B1 (en) * 2013-10-23 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną New application of N-[2-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]ethyl]-2-oxo-1,5,6,7-tetrahydrocyclopenta[b] pyridyno-3-carboxyamide
CN106455572B (en) 2014-06-06 2020-01-14 巴斯夫欧洲公司 Use of substituted oxadiazoles for combating phytopathogenic fungi
JP6556146B2 (en) 2014-08-26 2019-08-07 武田薬品工業株式会社 Heterocyclic compounds
JP6660060B2 (en) 2014-09-16 2020-03-04 セルジーン クオンティセル リサーチ,インク. Histone demethylase inhibitor
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017161033A1 (en) * 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN104262281A (en) * 2014-10-16 2015-01-07 湖南华腾制药有限公司 Preparation method of 2-bromo-4(4-ethoxyphenyl) oxazole
WO2016065583A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
EP3230281A1 (en) 2014-12-09 2017-10-18 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
MX2017009950A (en) 2015-02-02 2017-11-23 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors.
US10799479B2 (en) 2015-04-10 2020-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
WO2016179554A1 (en) 2015-05-07 2016-11-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX2017014299A (en) 2015-05-07 2018-08-09 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof.
WO2017014170A1 (en) * 2015-07-17 2017-01-26 武田薬品工業株式会社 Heterocyclic compound
WO2017014321A1 (en) 2015-07-17 2017-01-26 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as hdac inhibitors
NZ739026A (en) 2015-07-27 2019-03-29 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2018001196A (en) * 2015-07-27 2018-05-22 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same.
CN107980040A (en) 2015-07-27 2018-05-01 株式会社钟根堂 1,3,4- oxadiazoles sulfamide derivative as 6 inhibitor of histone deacetylase enzyme and the medical composition containing it
EP3331864A4 (en) * 2015-08-04 2019-05-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JPWO2017033946A1 (en) 2015-08-25 2018-06-07 武田薬品工業株式会社 Heterocyclic compounds
MX2018004038A (en) 2015-10-02 2019-07-18 Syngenta Participations Ag Microbiocidal oxadiazole derivatives.
WO2017055469A1 (en) 2015-10-02 2017-04-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
JP6697074B2 (en) 2015-10-12 2020-05-20 チョン クン ダン ファーマシューティカル コーポレーション Oxadiazole amine derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing the same
EP3167716A1 (en) 2015-11-10 2017-05-17 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
AR106679A1 (en) 2015-11-13 2018-02-07 Basf Se OXADIAZOLS REPLACED TO FIGHT FITOPATHOGEN FUNGI
BR112018009539A2 (en) 2015-11-13 2018-11-06 Basf Se use of compounds of formula i, compounds, mixture, agrochemical composition, use of compounds and method to combat phytopathogenic harmful fungi
BR112018008449A2 (en) 2015-11-19 2018-11-06 Basf Se use of formula compounds, formula compounds, mixture, agrochemical composition and method to combat phytopathogenic harmful fungi
UY36999A (en) 2015-12-02 2017-06-30 Syngenta Participations Ag Aryl oxadiazole derivatives fungicides
JP2019501171A (en) 2015-12-22 2019-01-17 シンジェンタ パーティシペーションズ アーゲー Pest control active pyrazole derivative
UY37062A (en) 2016-01-08 2017-08-31 Syngenta Participations Ag DERIVATIVES OF ARYL OXADIAZOL FUNGICIDAS
CN105503716A (en) * 2016-01-30 2016-04-20 天长市淳峰精细材料合成厂 Preparation method of 2,6-dicyanopyridine
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2017222950A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
AR109304A1 (en) 2016-08-10 2018-11-21 Sumitomo Chemical Co Oxadiazole compound and its use
WO2018057933A1 (en) * 2016-09-22 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes
US10435399B2 (en) 2017-07-31 2019-10-08 Takeda Pharmaceutical Company Limited HDAC6 inhibitory heterocyclic compound
CN112351981A (en) 2018-06-29 2021-02-09 先正达农作物保护股份公司 Microbicidal oxadiazole derivatives
KR20200012316A (en) * 2018-07-26 2020-02-05 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
WO2020032071A1 (en) * 2018-08-08 2020-02-13 日本農薬株式会社 Oxadiazoline compound or salt thereof, agricultural or horticultural bactericide containing said compound, and use method therefor
CN112194620A (en) * 2020-12-04 2021-01-08 苏州开元民生科技股份有限公司 Preparation method of 2-ethyl-4-cyanopyridine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
EP1212357B1 (en) 1999-09-08 2007-05-02 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
CA2590811C (en) * 2004-12-10 2013-07-30 Barbara Attenni Heterocycle derivatives as histone deacetylase (hdac) inhibitors
US20060223837A1 (en) 2005-03-24 2006-10-05 Ellen Codd Biaryl derived amide modulators of vanilloid VR1 receptor
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2013517281A (en) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. Compounds and methods
US20120322827A1 (en) 2010-01-13 2012-12-20 Erkan Baloglu Compounds and methods
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
CN103764635B (en) 2011-07-08 2016-01-20 诺华股份有限公司 New trifluoromethyl-oxadiazole derivative and the purposes in disease treatment thereof

Also Published As

Publication number Publication date
MX341133B (en) 2016-08-08
EP2533783B8 (en) 2015-12-16
CN103221047B (en) 2014-12-17
EA022964B1 (en) 2016-03-31
ZA201205125B (en) 2013-03-27
KR101781663B1 (en) 2017-09-25
EP2533783B1 (en) 2015-11-04
WO2011088181A1 (en) 2011-07-21
AU2011205283A1 (en) 2012-08-02
US20130059883A1 (en) 2013-03-07
ES2560627T3 (en) 2016-02-22
US20150038534A1 (en) 2015-02-05
BR112012017441A2 (en) 2016-04-19
EP2533783A1 (en) 2012-12-19
KR20130036093A (en) 2013-04-10
CN103221047A (en) 2013-07-24
IL220939A (en) 2016-11-30
MX2012008280A (en) 2012-11-23
WO2011088181A9 (en) 2013-01-31
EA201290638A1 (en) 2013-02-28
US8901156B2 (en) 2014-12-02
JP6017313B2 (en) 2016-10-26
SG182401A1 (en) 2012-08-30
AU2011205283B2 (en) 2014-07-10
EP2533783A4 (en) 2013-07-17
CA2787018A1 (en) 2011-07-21
BR112012017441B1 (en) 2019-11-19
JP2013517278A (en) 2013-05-16

Similar Documents

Publication Publication Date Title
HRP20190135T1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
HRP20181800T1 (en) Well
HRP20170903T1 (en) Substituted pyrrolidine-2-carboxamides
IL249669D0 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
HRP20161308T1 (en) 5-alkynyl-pyrimidines
HRP20160360T1 (en) Substituted imidazopyridazines
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
HRP20160094T1 (en) Triazine-oxadiazoles
IL222176A (en) Radioprotector compounds and methods
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
ZA201207727B (en) Morpholinylquinazolines
EP2547244A4 (en) Combination juicer-blender
EP2736330A4 (en) Compounds and methods
HK1179966A1 (en) Tetrahydro-pyrido-pyrimidine derivatives --
EP2566479A4 (en) Azaindazoles
GB201215746D0 (en) Rotocraft
HK1181747A1 (en) 1-hydroxyimino-3-phenyl-propanes 1--3--
EP2640189A4 (en) 3-deutero-pomalidomide
GB201108084D0 (en) Subbuffer objects
GB201205984D0 (en) No details
GB201001833D0 (en) Method
IL220939D0 (en) Compounds and methods
HK1176934A1 (en) Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes --[e]
GB201010196D0 (en) Methods
EP2747560A4 (en) Compounds and methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed